Breaking News Headlines Today

News about Johnson & Johnson

Stay current with all the latest and breaking news about Johnson & Johnson, compare headlines and perspectives between news sources on stories happening today. In total, 78 stories have been published about Johnson & Johnson which Ground News has aggregated in the past 3 months.

Covered Most By

Local News Publishers

Suggest a source

Looking for a source we don't already have? Suggest one here.

Insulet makes CFO change, appoints longtime J&J leader

Ana Maria Chadwick (left) and Flavia Pease (right). [Images courtesy of Insulet]Insulet (Nasdaq:PODD) announced today that it appointed Flavia Pease to succeed Ana Maria Chadwick as EVP and CFO. The transition goes into effect on Sept. 30, 2025, Chadwick intends to become a senior advisor to Insulet to ensure a smooth transition. “I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of sig…Johnson & Johnson · Acton Read Article

Appeals court rejects NJ pharma challenges to Medicare drug pricing

The basics: Third Circuit upholds lower court rulings against J&J, Bristol Myers, Novartis Program allows Medicare to negotiate drug prices under the IRA, saving seniors billions First round of negotiated prices starts 2026; discounts range 38%-79% on top drugs Pharma industry’s legal fight continues, Supreme Court last potential avenue A federal appeals court in Philadelphia rejected challenges by some of New Jersey’s biggest pharmaceutical co…Drug Prices · New Jersey Read Article

Unhealthy Business Environment: Another Blow To Nigeria’s Economy As Johnson & Johnson Plans Exit

The deepening unhealthy business environment in Nigeria is again about to compel another multinational company, Johnson & Johnson Innovative Medicines (J&J), to commence exit plan from Nigeria With the latest planned move by global healthcare giant Johnson & Johnson Innovative Medicines (J&J), on its preparation to shut down its operations in Nigeria, it will be the joining the likes of Norwegian energy company Equinor, Holcim AG, Diageo, Pick…Economy · Nigeria Read Article

J&J claims FDA okay for bladder cancer drug TAR-200

100% Center coverage: 1 sources

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.Johnson & Johnson · United States Read Article

From Clinic to Global Strategy: Dr. Caroline Blackie Named VP of Medical Affairs for Vision at J&J

Dr. Caroline Blackie. All photos provided by Dr. Blackie. Caroline Blackie, PhD, OD, MS, has long believed that “the grass is greener where you water it.” Today, as the newly appointed vice president of medical affairs for vision at Johnson & Johnson, she channels that philosophy into a global strategy for evidence-based eye care. With an impressive academic background spanning optometry, statistics, neurobiology and health informatics—and a car…Johnson & Johnson · New Brunswick Read Article

FDA Nod for J&J’s Drug/Device Treatment Gives Bladder Cancer Patients Another Option

100% Center coverage: 3 sources

A Johnson & Johnson cancer treatment that can spare certain bladder cancer patients from the radical step of surgical removal of the organ now has FDA approval. J&J’s drug/device combination product, Inlexzo, came from the 2019 acquisition of Taris Biomedical.Johnson & Johnson · United States See the Story

U.S. FDA Approval of INLEXZO™ (Gemcitabine Intravesical System) Set to Transform How Certain Bladder Cancers Are Treated

57% Center coverage: 14 sources

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinduction1Johnson & Johnson · Ohio See the Story

Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage

Lilly’s BTK Jaypirca will continue to compete with AbbVie and J&J’s Imbruvica and BeOne Medicines’s Brukinsa.Johnson & Johnson See the Story

Ronovo Surgical raises $67M, led by J&J venture arm

100% Center coverage: 1 sources

Ronovo, a Chinese surgical robotics company, will also team with a J&J subsidiary in Shanghai to sell Ronovo’s soft tissue platform and complementary J&J technologies.Johnson & Johnson · Shanghai Read Article

Osimertinib Plus Chemotherapy Offers Overall Survival Advantage for Patients with EGFR-Mutated Advanced NSCLC

100% Center coverage: 4 sources

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).Johnson & Johnson See the Story

News about Johnson & Johnson

News about Johnson & Johnson

Covered Most By

Local News Publishers

Insulet makes CFO change, appoints longtime J&J leader

Appeals court rejects NJ pharma challenges to Medicare drug pricing

Unhealthy Business Environment: Another Blow To Nigeria’s Economy As Johnson & Johnson Plans Exit

J&J claims FDA okay for bladder cancer drug TAR-200

From Clinic to Global Strategy: Dr. Caroline Blackie Named VP of Medical Affairs for Vision at J&J

FDA Nod for J&J’s Drug/Device Treatment Gives Bladder Cancer Patients Another Option

U.S. FDA Approval of INLEXZO™ (Gemcitabine Intravesical System) Set to Transform How Certain Bladder Cancers Are Treated

Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage

Ronovo Surgical raises $67M, led by J&J venture arm

Osimertinib Plus Chemotherapy Offers Overall Survival Advantage for Patients with EGFR-Mutated Advanced NSCLC

Covered Most By

Media Bias Breakdown

Breaking News Topics Related to Johnson & Johnson

Insulet makes CFO change, appoints longtime J&J leader

Appeals court rejects NJ pharma challenges to Medicare drug pricing

Unhealthy Business Environment: Another Blow To Nigeria’s Economy As Johnson & Johnson Plans Exit

J&J claims FDA okay for bladder cancer drug TAR-200

From Clinic to Global Strategy: Dr. Caroline Blackie Named VP of Medical Affairs for Vision at J&J

FDA Nod for J&J’s Drug/Device Treatment Gives Bladder Cancer Patients Another Option

U.S. FDA Approval of INLEXZO™ (Gemcitabine Intravesical System) Set to Transform How Certain Bladder Cancers Are Treated

Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage

Ronovo Surgical raises $67M, led by J&J venture arm

Osimertinib Plus Chemotherapy Offers Overall Survival Advantage for Patients with EGFR-Mutated Advanced NSCLC